ZACHARIOUDAKI Vassiliki, BIOLOGIST, PhD

Short CV

CURRENT POSITION (since March 2022):

GMP Lab Supervisor, QM – Cell Processing Biologist

Permanent Staff, National Health system (ESY)

- University General Hospital of Patras (UGHP)
- Institute of Cell Therapy (ICT), University of Patras

JOB DESCRIPTION:

- Supervision of Cell Therapy Production in the GMP Laboratory of ICT – Head Production Scientist
- Cell Processing Department UGHP – Cryopreservation, Storage and Transportation of Bone Marrow Transplants & Donor Lymphocytes (SoHOs)
- Quality Manager - GMP Lab
- Responsible for Bone Marrow Transplant Reception from abroad
- Responsible for ATMP Reception from abroad
- Guest lecturer in MSc Program "From Bench to Bedside: Cell and Gene Therapies and Good Manufacturing Practices"

Vassiliki Zacharioudaki holds a Degree in Biology from Aristotle University of Thessaloniki, Greece and a MSc and PhD in Molecular Medicine, from Faculty of Medicine, University of Crete, Greece and is an expert in Immunology, Cancer Biology and Product Development.

NATIONAL / INTERNATIONAL STANDARDS:

- FACT-JACIE: 18/07/2024
- GMP CERTIFICATE: 09/08/2024
- ISO for Clinical Trials: 01/06/2023

PREVIOUS TRAINING:

The main projects of her PhD research (2005-2009) were focused on Cell Signaling and Cell Metabolism in Chronic Inflammatory Diseases and Lymphomas. She has research experience as a PhD candidate in Tufts Medical Center, Boston, USA (2008-2009), where she mainly focused on the development of macrophage tolerance during inflammatory response. Her principal post-doctoral projects were dedicated to:

- Nanobody Development (2010-2014), Vrije Universiteit Brussel, Belgium and Visiting Researcher, Imperial College London, UK, and concerned the design, development, production, and valorization of biomarker-specific antibody derivatives to be used as molecular tools in solid tumor diagnosis and prognosis.
- Intestinal Mucosal Immunology and Microbiota interactions (2015 - 2017), Institut Pasteur de Lille, France, and were mainly focused on the development of Group B Streptococcus colonization and neonatal invasive disease model with the use of SPF and Germ-Free mice, for the description of the immune response in the gut of both mother and child.